<DOC>
	<DOCNO>NCT02834260</DOCNO>
	<brief_summary>Immune rejection episode penetrate keratoplasty occur 30 % patient constitute one main factor reduce graft survival . They mainly occur first 18 month . Prevention usually rely topical treatment dexamethasone prednisolone standard risk patient . Eye drop instill three time day least 3 month taper . OZURDEX absorbable small implant release total 700 microgram dexamethasone several month . It indicate intravitreal injection treat macular edema . The investigator hypothesize implant could use subconjunctival injection corneal graft , prevent immune rejection avoid repeat eyedrop instillation .</brief_summary>
	<brief_title>Immunosuppression During Penetrating Keratoplasty , Using Subconjunctival Implant Releasing Dexamethasone : Tolerance Safety Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Keratoconus</mesh_term>
	<mesh_term>Fuchs ' Endothelial Dystrophy</mesh_term>
	<mesh_term>Corneal Dystrophies , Hereditary</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Keratoconus Fuch 's dystrophy Hereditary stromal dystrophy Age 18 year old Signed informed consent Affiliated French Social Security Hypersensitivity Dexamethasone excipients ( polylactic glycolic acid ) Active ocular periocular infection Advanced glaucoma History herpetic zoster keratitis Retinal disease intravitreal injection Ozurdex plan next 34 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>absorbable implant</keyword>
	<keyword>subconjunctival</keyword>
	<keyword>immune rejection</keyword>
	<keyword>safety profile</keyword>
	<keyword>dexamethasone</keyword>
</DOC>